Augmentation of APOε2 is being tested by Lexeo Therapeutics in a small Phase 1 trial (Table 4) to assess the safety and toxicity of intrathecal administration of AAVrh.10hAPOE2 (LX1001) in APOE4 homozygous patients with AD Stages 3–4. The gene discussed is APOE; the disease is Alzheimer disease.